Omalizumab for severe asthma: efficacy beyond the atopic patient? - Wikidata - awgldk - TriplyDB

Omalizumab for severe asthma: efficacy beyond the atopic patient?

Omalizumab for severe asthma: efficacy beyond the atopic patient?

http://www.wikidata.org/entity/Q38201304

about

A review of omalizumab for the management of severe asthma Intranasal exposure to monoclonal antibody Fab fragments to Japanese cedar pollen Cry j1 suppresses Japanese cedar pollen-induced allergic rhinitis A review of standard pharmacological therapy for adult asthma – Steps 1 to 5.The asthma COPD overlap syndrome (ACOS).dIvergEnt: How IgE Axis Contributes to the Continuum of Allergic Asthma and Anti-IgE Therapies.Nonallergic rhinitis and lower airway disease.Pharmacokinetics, pharmacodynamics and clinical efficacy of omalizumab for the treatment of asthma.Omalizumab Is Equally Effective in Persistent Allergic Oral Corticosteroid-Dependent Asthma Caused by Either Seasonal or Perennial Allergens: A Pilot Study.Role of IL-15 in the modulation of TGF-β1-mediated inflammation in asthma.Overlapping Effects of New Monoclonal Antibodies for Severe Asthma.Moving toward consensus on diagnosis and management of severe asthma in adults.Omalizumab for Severe Asthma: Beyond Allergic Asthma The prostaglandin D receptor 2 pathway in asthma: a key player in airway inflammation

P2860

Q26741315-5469CD41-E12C-4E14-BF7B-26A300F1DFA0 Q36830128-8C2C3B33-650D-4A75-9BEB-40B2B7A05FB9 Q38364832-DB66F716-1F77-4B55-9E90-19830825609D Q38364870-09A01878-C4FC-4EAF-91A5-6D83A1BB7E56 Q38715930-85E7929F-773D-499E-9A62-0971AAFB7CB6 Q38903455-F49D0791-1C11-4C7E-A674-8AA1AD65C4BF Q38982481-4B1EA817-7028-44E6-8B4B-27D260CC65AA Q42293331-5C6C10AE-6759-479C-9B7B-496313CAE9CB Q44755593-54F6BE95-36EA-4F11-B988-E428910BF333 Q47921576-59714902-4F34-47C4-A1D8-8BFC20DB512D Q50106766-94B1542A-2252-4E66-B8E6-8A686ED55831 Q57493273-9042D00B-7C22-492A-9A40-4CE43594EC68 Q58795817-15225233-99EF-4EDC-926D-71F8E34EF12F

P2860

Omalizumab for severe asthma: efficacy beyond the atopic patient?

http://www.wikidata.org/entity/Q38201304

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Omalizumab for severe asthma: efficacy beyond the atopic patient?

@en

type

label

Omalizumab for severe asthma: efficacy beyond the atopic patient?

@en

prefLabel

Omalizumab for severe asthma: efficacy beyond the atopic patient?

@en

P1433

Q38201304-D253B04F-0E07-41C3-B70E-25262E3C8DA4

P1476

Q38201304-A7ABBC27-0D6A-4485-A9E7-F8B532A3394D

P2093

Q38201304-AE5CC17E-5FB4-4DD5-B2E3-68B6C67461EA

P2860

Q38201304-0774764D-9A78-454C-B4F8-3E75C8AC7F67

Q38201304-1175C9DE-A128-4E58-90E0-BEE246BFC61F

Q38201304-12CF8788-09C6-4A73-A8D5-483D1F78F902

Q38201304-12D7DC08-3DED-4AAD-8B1D-25CF90883E2D

Q38201304-16B371CC-663C-4E82-A9E7-AABAD5B7DDB5

Q38201304-1AC2368B-6D75-4356-8A5B-9A3FF9F3B170

Q38201304-202EACBA-19F0-4033-B921-5C7D2915F0E7

Q38201304-2A771F3F-5201-4A4B-8A03-33BB06FABBDD

Q38201304-2A85193A-4E0E-4A29-BC88-70AF56875A8D

Q38201304-2BE6FC3B-4EB7-4BFD-9D3F-021B17E3C815

P2888

Q38201304-2A5606C4-84FB-431A-BA1F-E6F9768AB507

P304

Q38201304-6E105315-AA4E-4DD8-AC11-B6070A32F2F3

P31

Q38201304-FC855385-B90E-4701-86DD-3AA00E7FDF99

P356

Q38201304-0A78CFF6-C3CD-48C3-9B11-99B42F0A6610

P433

Q38201304-20B0425F-B50E-4087-94C6-8A2E8C24086C

P478

Q38201304-5C09E79D-440D-4BF1-AB18-CBF0FB35416E

P577

Q38201304-EE31A7C4-8234-46A1-8B88-FA7160490524

P6179

Q38201304-D5603146-51F7-4F6C-8FE6-1BDB22CC96C1

P698

Q38201304-5C1E5407-1157-42FB-8749-4EEC56E98218

P921

Q38201304-0EF683E8-FA97-49D5-9144-0049B3E74354

P356

S40265-014-0203-Y

P1433

P1476

Omalizumab for severe asthma: efficacy beyond the atopic patient?

@en

P2093

Christian Domingo

http://www.w3.org/2001/XMLSchema#string

P2860

The pharmacological basis of anti-IgE therapy

Staphylococcus aureus colonization and IgE antibody formation to enterotoxins is increased in nasal polyposis

Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids

IgE alone promotes human lung mast cell survival through the autocrine production of IL-6.

Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: real-life data.

The immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: more similarities than differences.

Phenotypic differences between pediatric and adult asthma.

Italian real-life experience of omalizumab.

Omalizumab and asthma control in patients with moderate-to-severe allergic asthma: a 6-year pragmatic data review.

The oral corticosteroid-sparing effect of omalizumab in children with severe asthma.

P2888

s40265-014-0203-y

P304

521-533

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40265-014-0203-Y

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P577

2014-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1014977970

http://www.w3.org/2001/XMLSchema#string

P698

24691707

http://www.w3.org/2001/XMLSchema#string

P921